Tenax Therapeutics Inc TENX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky
-
TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law
-
TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)
-
TENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeutics
-
Tenax Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Tenax Therapeutics (TENX)
-
Tenax Therapeutics Says Late-Stage Trial Misses Primary, Secondary Endpoints
Trading Information
- Previous Close Price
- $1.86
- Day Range
- $1.80–1.91
- 52-Week Range
- $1.31–19.40
- Bid/Ask
- $1.86 / $1.88
- Shares Outstanding
- 37.42M
- Market Cap
- $69.98M
- Volume/Avg
- 2M / 5M
Key Statistics
- Price/Earnings (Normalized)
- 0.79
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 16
- Website
- https://www.tenaxthera.com
Valuation
|
Metric
|
TENX
|
|---|---|
Price/Earnings (Normalized) | 0.79 |
Price/Book Value | 0.53 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
TENX
Financial Strength
|
Metric
|
TENX
|
|---|---|
Quick Ratio | 13.99 |
Current Ratio | 14.52 |
Interest Coverage | — |
Quick Ratio
TENX
Profitability
|
Metric
|
TENX
|
|---|---|
Return on Assets (Normalized) | −43.28% |
Return on Equity (Normalized) | −45.99% |
Return on Invested Capital (Normalized) | −49.59% |
Return on Assets
TENX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?kT^Mss | LOCK|#!v% | $129B | |||
| Moderna Inc
MRNA
| LOCK|v@bJ^B | LOCK|^K | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Cwp#%X | LOCK|Sm>S! | $77B | |||
| argenx SE ADR
ARGX
| LOCK|HkLZ^# | LOCK|%?$ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|lHj$Qc | LOCK|@> | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#fDn##& | LOCK|&N?r< | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^YZhMRz | LOCK|f<wl< | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|sK?r#&? | LOCK|!R> | $24B | |||
| Incyte Corp
INCY
| LOCK|&!&d!# | LOCK|!&K | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|ZdSHSx% | LOCK|QX | $14B |
United States